Feasibility of the Ultravision™ System in Low Pressure Laparoscopic Cholecystectomy Compared to Airseal® IFS

NCT ID: NCT04162106

Last Updated: 2019-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-30

Study Completion Date

2020-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This post-market clinical study is designed to evaluate the effectiveness of the Ultravision™ System when compared to the Airseal® iFS within an approved indication for use, namely laparoscopic cholosystectomy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary hypothesis being tested in this study is that Ultravision facilitates the utilization of lower pneumoperitoneal pressures whilst maintaining an adequate visual field throughout the procedure with low demand for CO2 replenishment to maintain pneumoperitoneal pressure. Comparisons in terms of surgical field visualization, procedure times, and CO2 consumption will be conducted in order to determine whether or not any clinical benefits are derived from the use of the Ultravision™ System compared to the Airseal® iFS. Low pressure laparoscopy for this study is set at 10mmHg. This is a prospective, open-label, randomized controlled study. The study will include two study arms. Patients undergoing laparoscopic cholecystectomy will be randomized to either "Ultravision" (study arm 1) or Airseal® iFS (study arm 2). Both groups will conduct the procedure at 10mmHg, considered to be low pressure/low impact laparoscopic surgery. The study will enroll 30 patients, 15 per group. Both devices are being used according to their cleared label claims.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Laparoscopic Cholecystectomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ultravision™ System

Smoke management during laparoscopic cholecystectomy performed with the Ultravision™ System

Group Type ACTIVE_COMPARATOR

Smoke management during laparoscopic cholecystectomy using the Ultravision™ System

Intervention Type DEVICE

The Ultravision™ System will be used during the procedure to manage smoke generated as a result of the use of diathermy.

Airseal® iFS

Smoke management during laparoscopic cholecsystectomy performed with the Airseal® iFS

Group Type ACTIVE_COMPARATOR

Smoke management during laparoscopic cholecystectomy using the Airseal® iFS

Intervention Type DEVICE

The Airseal® iFS will be used during the procedure to manage smoke generated as a result of the use of diathermy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Smoke management during laparoscopic cholecystectomy using the Ultravision™ System

The Ultravision™ System will be used during the procedure to manage smoke generated as a result of the use of diathermy.

Intervention Type DEVICE

Smoke management during laparoscopic cholecystectomy using the Airseal® iFS

The Airseal® iFS will be used during the procedure to manage smoke generated as a result of the use of diathermy.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Is 18 years or older
* Provide written informed consent prior to trial procedures after studies indicate that the patient needs the prescribed procedure
* Agrees to attend all follow-up assessments
* Is indicated for elective laparoscopic cholecystectomy

Exclusion Criteria

* Existing comorbidities that would contraindicate them for laparoscopic surgery
* Patient anatomy i.e. abdominal wall thickness that exceeds the working length of the Ionwand catheter identified intraoperatively
* Body Mass Index \> 50
* Be pregnant (if female)
* Has a condition of unrelated chronic pain requiring medication
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alesi Surgical Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Duke Regional Hospital

Durham, North Carolina, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jin S Yoo, MD

Role: CONTACT

919-470-7038

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Pro00103233

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.